TEKLA LIFE SCIENCES INVESTOR

TEKLA LIFE SCIENCES INVESTOR (HQL)

$13.62

+0.01

(+0.07%)

Market is closed - opens 7 PM, 08 Jun 2023

Insights on Tekla Life Sciences Investors

  • Vs APO

    In the last 1 year, Apollo Global Management Inc - Class A has given 20.1% return, outperforming this stock by 25.9%

  • Vs KKR

    In the last 3 years, KKR & Co. Inc. has given 33.5% return, outperforming this stock by 55.7%

Performance

  • $13.50
    $13.75
    $13.62
    downward going graph

    0.88%

    Downside

    Day's Volatility :1.82%

    Upside

    0.95%

    downward going graph
  • $11.94
    $14.96
    $13.62
    downward going graph

    12.33%

    Downside

    52 Weeks Volatility :20.19%

    Upside

    8.96%

    downward going graph

Returns

PeriodTEKLA LIFE SCIENCES INVESTORRussel 2000Index (Russel 2000)
3 Months
-3.68%
-5.8%
-5.8%
6 Months
-8.53%
-2.1%
-2.1%
1 Year
-5.81%
-7.8%
-7.8%
3 Years
-22.63%
17.4%
17.4%

Highlights

Market Capitalization
357.7M
Book Value
$15.5
Dividend Share
1.47
Dividend Yield
9.63%
Earnings Per Share (EPS)
-4.33
PEG Ratio
0.0
Profit Margin
0.0%
Operating Margin TTM
-99.04%
Return On Assets TTM
-0.39%
Return On Equity TTM
-22.71%
Revenue TTM
3.0M
Revenue Per Share TTM
0.12
Quarterly Revenue Growth YOY
34.5%
Gross Profit TTM
3.0M
Diluted Eps TTM
-4.33
Quarterly Earnings Growth YOY
-0.66
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Technicals Summary

Sell

Neutral

Buy

Tekla Life Sciences Investors is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
TEKLA LIFE SCIENCES INVESTOR
TEKLA LIFE SCIENCES INVESTOR
-2.02%
-8.53%
-5.81%
-22.63%
-27.37%
Blackstone Inc
Blackstone Inc
7.68%
12.57%
-27.06%
47.01%
167.61%
KKR & Co. L.P.
KKR & Co. L.P.
10.59%
15.16%
-4.25%
72.02%
142.57%
BlackRock, Inc.
BlackRock, Inc.
6.5%
-3.42%
0.78%
22.89%
24.73%
Apollo Asset Management Inc
Apollo Asset Management Inc
14.72%
15.54%
20.06%
34.29%
120.35%
 Brookfield Corp
Brookfield Corp
-0.41%
-5.68%
-5.68%
-5.68%
-5.68%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
TEKLA LIFE SCIENCES INVESTOR
TEKLA LIFE SCIENCES INVESTOR
5.75
NA
0.0
0.0
-0.23
0.0
0.1
15.5
Blackstone Inc
Blackstone Inc
107.3
107.3
1.27
4.39
0.03
0.02
0.05
9.95
KKR & Co. L.P.
KKR & Co. L.P.
48.02
NA
2.81
3.55
-0.04
-0.01
0.01
21.54
BlackRock, Inc.
BlackRock, Inc.
20.58
20.58
13.91
35.03
0.12
0.03
0.03
251.57
Apollo Asset Management Inc
Apollo Asset Management Inc
8.99
NA
1.37
6.57
-0.11
-0.01
0.02
14.23
 Brookfield Corp
Brookfield Corp
70.39
70.39
NA
3.84
0.02
0.02
0.01
25.54
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
TEKLA LIFE SCIENCES INVESTOR
TEKLA LIFE SCIENCES INVESTOR
NA
$357.7M
-27.37%
5.75
0.0%
Blackstone Inc
Blackstone Inc
Buy
$104.4B
167.61%
107.3
14.46%
KKR & Co. L.P.
KKR & Co. L.P.
Buy
$61.9B
142.57%
48.02
-8.27%
BlackRock, Inc.
BlackRock, Inc.
Buy
$101.3B
24.73%
20.58
28.13%
Apollo Asset Management Inc
Apollo Asset Management Inc
Buy
$40.3B
120.35%
8.99
-11.79%
 Brookfield Corp
Brookfield Corp
Buy
$48.5B
-5.68%
70.39
0.85%

Corporate Announcements

  • TEKLA LIFE SCIENCES INVESTOR Dividends March,2023

    In the quarter ending March,2023. TEKLA LIFE SCIENCES INVESTOR has declared dividend of $0.33

    Read More

Company Information

tekla life sciences investors is a closed-ended equity mutual fund launched and managed by tekla capital management llc. the fund invests in public equity markets across the globe. it seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. the fund primarily invests in growth stocks of small cap companies. it employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. the fund benchmarks the performance of its portfolio against the nasdaq biotech index and the s&p 500 index. it was form

Organization
TEKLA LIFE SCIENCES INVESTOR
Employees
0
CEO
Dr. Daniel R. Omstead M.S, Ph.D.
Industry
Miscellaneous

FAQs